U.S., July 24 -- ClinicalTrials.gov registry received information related to the study (NCT07079644) titled 'Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Database' on June 10.
Brief Summary: The purpose of this study is to investigate the real-world clinical outcomes of individuals that have been diagnosed with advanced melanoma who were treated with Nivolumab in combination with Relatlimab, Nivolumab in combination with Ipilimumab, immuno-oncology monotherapy or BRAF/MEK inhibitors therapy
Study Start Date: Nov. 29, 2024
Study Type: OBSERVATIONAL
Condition:
Advanced Melanoma
Intervention:
BIOLOGICAL: Nivolumab + Relatlimab
As per product label
BIOLOGICAL: Nivolumab + Ipili...